camoteskimab vs EVO301

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: IL-18 · full Atopic Dermatitis pipeline

camoteskimab

Developed by Apollo Therapeutics

Phase 2 in Atopic Dermatitismonoclonal antibody
Partial signal

NCT06436183 · Phase 2 · completed

The study was randomized, quadruple-blinded, and placebo-controlled, with 62 participants, and used a clinical EASI measure as its primary endpoint.

Next expected readout: October 2027 · NCT07599813 (registry estimate)

No aligned efficacy figure on record for this race.

EVO301

Developed by Evommune and partners

Phase 2 in Atopic Dermatitisfusion protein
Partial signal

NCT06723405 · Phase 2 · completed

Participants were randomized and blinded to drug or placebo, and disease severity improved significantly more with EVO301. However, the study was small, which limits confidence in the size of the benefit.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Eczema Area and Severity Index (EASI) (12 weeks): Placebo-adjusted improvement in EASI at Week 12: 33% (95% CI -50, -17; p<0.01) (met)

Result source: NCT06723405

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointcamoteskimabEVO301
EASI-75—Not reported—Not reported
IGA 0/1 with 2-point improvement—Not reported—Not reported
EASI-90—Not reported—Not reported
EASI, % change—Not reported—Not reported

EASI-75

camoteskimab
—Not reported
EVO301
—Not reported

IGA 0/1 with 2-point improvement

camoteskimab
—Not reported
EVO301
—Not reported

EASI-90

camoteskimab
—Not reported
EVO301
—Not reported

EASI, % change

camoteskimab
—Not reported
EVO301
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

camoteskimab: no structured comparison results are available for Atopic Dermatitis.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

EVO301

EASI 33% @ 12wk
percent change · % of baseline
No placebo or comparator arm
NCT06723405 · Phase 2 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: camoteskimab's landscape · EVO301's landscape